Cyfuse Biomedical K.K. (JP:4892)

:4892

4892

Cyfuse Biomedical K.K.

RESEARCH TOOLSreports

Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥516.00 - ¥948.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.74B

Enterprise Value¥2.68B

Total Cash (Recent Filing)¥2.70B

Total Debt (Recent Filing)¥766.00M

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-101.10

Shares Outstanding10,091,200

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue ReboundA very large revenue recovery in 2025 demonstrates traction for the company’s offerings and indicates demand recovery in its target end markets. Sustained revenue growth provides a platform to scale operations, improve operating leverage, and reduce reliance on external financing over the next 2–6 months if continued.

Niche Platform Business ModelCyfuse’s scaffold-free 3D cell assembly platform targets regenerative medicine and research customers, creating product stickiness and specialized know-how. This technology-led, platform-centric model supports recurring product, services, and collaboration revenue streams that are structurally durable versus one-off product sellers.

Manageable Leverage And Asset BaseDebt-to-equity around 0.48 with a sizable equity and asset base gives the company financial capacity to fund near-term operations and R&D. While losses persist, this balance sheet scale reduces immediate solvency risk and provides runway to execute on commercialization and partnerships over the coming months.

Bears Say

Deep, Persistent UnprofitabilityExtremely negative operating and net margins show the business is not generating returns on revenue; such magnitude of losses is structural and requires either sustained revenue growth, material margin improvement, or dilution via financing to restore profitability, risking long-term shareholder value.

Continued Cash BurnPersistently negative operating and free cash flow means the company depends on external funding to sustain operations and R&D. Continued cash burn raises financing risk and can force dilutive capital raises or constrain strategic investments, weakening long-term execution if not reversed.

Weak Margin ScalabilityDeclining gross margin and very large operating losses indicate the cost structure has not scaled with revenue. If fixed and variable costs remain elevated relative to sales, the company will struggle to convert top-line gains into sustainable profits, limiting durable improvement in returns.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥516.00 and its highest was ¥948.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.74B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 19, 2026 which is in 73 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on May 15, 2026. The company reported -¥22.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.56.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,091,200 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥22.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.622%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.